Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥25.22B
Enterprise Value¥20.95K
Total Cash (Recent Filing)¥3.25B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.10
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.75
Price to Sales (P/S)11.09
P/FCF Ratio-43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Conservative, Low‑leverage Balance SheetEffectively no debt and substantial equity reduced solvency risk and provide durable financial flexibility. This strengthens the company’s ability to fund ongoing R&D, absorb operating losses without immediate refinancing, and buy time to execute commercialization strategies over the next few quarters.
Sizable Gross Profit BaseA meaningful gross profit base indicates underlying product economics that can support margins once fixed costs are managed and scale improves. Sustained gross profitability provides a foundation for operating leverage and eventual recovery of operating income when revenue trends stabilize.
Demonstrated Ability To Generate Positive Cash Flow In Stronger PeriodsThe prior ability to produce positive operating and free cash flow in 2024 shows operations can become cash generative under improved conditions. This suggests operational levers and revenue sensitivity exist that could reduce burn and restore self-funded growth if product uptake and cost control recover.
Bears Say
Widening Operating LossesA rapid swing to materially larger net losses indicates deteriorating operating performance and limited near-term profitability visibility. Persistent losses erode investor capital, constrain reinvestment capacity, and raise the bar for achieving sustainable margins without substantive revenue recovery or structural cost reductions.
Accelerating Cash Burn And Negative Free Cash FlowSharp deterioration in operating and free cash flow increases reliance on balance sheet resources or external financing. Accelerating cash burn is a structural risk for biotech firms, potentially forcing dilutive financing or project prioritization that can slow commercialization and damage long‑term growth prospects.
Eroding Equity And Negative Returns On EquityDeclining equity from accumulated losses and re-emergent negative ROE signal the balance sheet is being consumed to cover operating shortfalls. Over time this reduces the firm’s buffer against shocks, limits strategic optionality, and heightens the urgency for sustainable profit generation or new capital.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥25.22B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on May 01, 2026. The company reported -¥4.39 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.39 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.34%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.